Galectin Therapeutics Receives FDA Feedback to Advance Belapectin Development
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 22 2025
0mins
Should l Buy GALT?
Source: NASDAQ.COM
- Positive FDA Feedback: Galectin Therapeutics received written feedback from the FDA on its Belapectin development program, indicating alignment on the proposed patient population for enrollment in a registration trial, which enhances the company's confidence in treating MASH cirrhosis.
- Fast Track Designation: Belapectin has been granted Fast Track designation by the FDA as a potential treatment for MASH cirrhosis, highlighting its market potential in a space with limited therapeutic options, which could lead to new revenue streams for the company.
- Financial Support: Galectin entered into a new $10 million unsecured convertible line of credit agreement with Chairman Richard E. Uihlein, expected to provide sufficient funding to support operations through at least March 2027, thereby strengthening its research and market advancement capabilities.
- Clinical Trial Planning: The company plans to extend the centralized, blinded endoscopy review method agreed upon with the FDA into its next study, aiming to optimize trial design and enhance Belapectin's clinical efficacy through new biomarker data.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GALT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GALT
Wall Street analysts forecast GALT stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.680
Low
11.00
Averages
11.00
High
11.00
Current: 2.680
Low
11.00
Averages
11.00
High
11.00
About GALT
Galectin Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing therapies to improve the lives of patients with chronic liver disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are key mediators of biologic and pathologic functions. The Company’s lead drug, belapectin, is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases for which it has Fast Track designation by the U.S. Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis, the most advanced form of MASH-related fibrosis. The Company's additional development programs are in the treatment of combination immunotherapy for advanced head and neck cancers and other malignancies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Galectin Therapeutics Under Investigation, Stock Plummets 28.9%
- Investigation Launched: Pomerantz LLP is investigating Galectin Therapeutics Inc. and its executives for potential securities fraud or other unlawful business practices, which could undermine investor confidence and lead to further stock volatility.
- FDA Response: On December 19, 2025, Galectin announced that the FDA provided a written response to its meeting request regarding the belapectin development program, indicating alignment on the proposed patient population for a registration trial, but unresolved key aspects of the trial design may delay clinical trial progress.
- Stock Price Drop: Following the FDA news, Galectin's stock price fell by $1.78, or 28.9%, closing at $4.38 per share, reflecting market concerns and diminished confidence in the company's future prospects.
- Legal Matters: Pomerantz LLP, a prominent securities class action law firm, has been advocating for the rights of securities fraud victims for over 85 years; unfavorable investigation outcomes could lead to significant damages against the company, further impacting its financial health.
See More
Galectin Therapeutics Under Investigation, Stock Plummets 28.9%
- Securities Fraud Investigation: Pomerantz LLP is investigating Galectin Therapeutics and its executives for potential securities fraud and other unlawful business practices, which could undermine investor confidence and lead to stock volatility.
- FDA Meeting Update: On December 19, 2025, Galectin announced that the FDA provided a written response to its Type C meeting request regarding the development program for belapectin, indicating alignment on the patient population but leaving key trial design aspects unresolved.
- Stock Price Plunge: Following the FDA news, Galectin's stock price fell by $1.78, or 28.9%, closing at $4.38 per share, reflecting market concerns about the company's future prospects.
- Legal Background: Pomerantz LLP, a prominent securities class action law firm with over 85 years of experience, focuses on advocating for victims of securities fraud and corporate misconduct, potentially offering legal support to affected investors.
See More
Galectin Therapeutics Faces 28.9% Stock Drop Following FDA Response on Belapectin Trial
- Significant Stock Decline: Galectin Therapeutics experienced a stock price drop of $1.78, or 28.9%, closing at $4.38 per share following the FDA's response regarding its belapectin clinical trial, indicating market concerns about the company's future prospects.
- Change in FDA Communication: The FDA's conversion of Galectin's request for an in-person or teleconference meeting into a written response highlights unresolved issues in key trial design aspects, which may impact the progress of its clinical trials and registration applications.
- Follow-Up Meeting Plans: Galectin plans to pursue a follow-up Type C meeting to finalize remaining components of its clinical trial design, and while there is alignment with the FDA on the proposed patient population, unresolved key design issues could delay trial progress.
- Legal Investigation Initiated: Pomerantz LLP is investigating whether Galectin and its executives have engaged in securities fraud or other unlawful business practices, potentially exposing investors to further legal risks and financial losses.
See More
Galectin Therapeutics Faces 28.9% Stock Drop Following FDA Response on Belapectin Trial
- Significant Stock Drop: Galectin Therapeutics experienced a stock price decline of $1.78, or 28.9%, closing at $4.38 per share following the FDA's feedback on its belapectin clinical trial design, indicating market concerns about the company's future prospects.
- Change in FDA Communication: The FDA converted the company's initial request for an in-person or teleconference meeting into a written response, and while there is alignment on the proposed patient population for a registration trial, unresolved key aspects of the trial design may hinder future clinical progress.
- Legal Investigation Initiated: Pomerantz LLP is investigating whether Galectin and its executives have engaged in securities fraud or other unlawful business practices, which could expose the company to legal risks and further impact shareholder confidence.
- Increased Investor Scrutiny: The sharp stock decline and the initiation of a legal investigation have significantly heightened investor attention on Galectin, potentially leading to more investors seeking to join class action lawsuits to protect their interests.
See More
Galectin Secures $10M Credit Line, FDA Provides Guidance on Regulatory Pathway
- Credit Support: Galectin Therapeutics Inc. secured a $10 million credit line, ensuring funding to cover expected expenditures through March 2027, thereby enhancing its R&D capabilities in the NASH cirrhosis treatment space.
- FDA Guidance: The FDA provided written feedback on Galectin's regulatory pathway for belapectin, marking a significant advancement in the company's drug development efforts, which could expedite its product's market entry.
- Market Reaction: Galectin's stock rose by 1% to $4.03 in Wednesday's trading, reflecting investor optimism regarding its financing and FDA support.
- Strategic Implications: This credit line and FDA guidance will provide Galectin with essential funding and regulatory backing in the competitive biopharmaceutical market, aiding its future clinical trials and market launch efforts.
See More
Galectin Therapeutics (GALT) Price Target Raised by 83.33% to $11.22
Price Target Update: The average one-year price target for Galectin Therapeutics (NasdaqCM:GALT) has been raised to $11.22 per share, reflecting an 83.33% increase from the previous estimate of $6.12, with a potential upside of 156.16% from the last closing price of $4.38.
Fund Sentiment: There are currently 122 funds reporting positions in Galectin Therapeutics, a decrease of 27 funds (18.12%) from the last quarter, while the average portfolio weight dedicated to GALT has increased by 41.86%.
Shareholder Activity: Notable shareholders include Vanguard Total Stock Market Index Fund and Advisor Group Holdings, with varying changes in their shareholdings, including increases in portfolio allocations for some funds.
Market Outlook: The put/call ratio for GALT stands at 0.09, indicating a bullish sentiment among investors, suggesting optimism about the stock's future performance.
See More
Galectin Therapeutics Under Investigation, Stock Plummets 28.9%
- Investigation Launched: Pomerantz LLP is investigating Galectin Therapeutics Inc. and its executives for potential securities fraud or other unlawful business practices, which could undermine investor confidence and lead to further stock volatility.
- FDA Response: On December 19, 2025, Galectin announced that the FDA provided a written response to its meeting request regarding the belapectin development program, indicating alignment on the proposed patient population for a registration trial, but unresolved key aspects of the trial design may delay clinical trial progress.
- Stock Price Drop: Following the FDA news, Galectin's stock price fell by $1.78, or 28.9%, closing at $4.38 per share, reflecting market concerns and diminished confidence in the company's future prospects.
- Legal Matters: Pomerantz LLP, a prominent securities class action law firm, has been advocating for the rights of securities fraud victims for over 85 years; unfavorable investigation outcomes could lead to significant damages against the company, further impacting its financial health.
See More
Galectin Therapeutics Under Investigation, Stock Plummets 28.9%
- Securities Fraud Investigation: Pomerantz LLP is investigating Galectin Therapeutics and its executives for potential securities fraud and other unlawful business practices, which could undermine investor confidence and lead to stock volatility.
- FDA Meeting Update: On December 19, 2025, Galectin announced that the FDA provided a written response to its Type C meeting request regarding the development program for belapectin, indicating alignment on the patient population but leaving key trial design aspects unresolved.
- Stock Price Plunge: Following the FDA news, Galectin's stock price fell by $1.78, or 28.9%, closing at $4.38 per share, reflecting market concerns about the company's future prospects.
- Legal Background: Pomerantz LLP, a prominent securities class action law firm with over 85 years of experience, focuses on advocating for victims of securities fraud and corporate misconduct, potentially offering legal support to affected investors.
See More
Galectin Therapeutics Faces 28.9% Stock Drop Following FDA Response on Belapectin Trial
- Significant Stock Decline: Galectin Therapeutics experienced a stock price drop of $1.78, or 28.9%, closing at $4.38 per share following the FDA's response regarding its belapectin clinical trial, indicating market concerns about the company's future prospects.
- Change in FDA Communication: The FDA's conversion of Galectin's request for an in-person or teleconference meeting into a written response highlights unresolved issues in key trial design aspects, which may impact the progress of its clinical trials and registration applications.
- Follow-Up Meeting Plans: Galectin plans to pursue a follow-up Type C meeting to finalize remaining components of its clinical trial design, and while there is alignment with the FDA on the proposed patient population, unresolved key design issues could delay trial progress.
- Legal Investigation Initiated: Pomerantz LLP is investigating whether Galectin and its executives have engaged in securities fraud or other unlawful business practices, potentially exposing investors to further legal risks and financial losses.
See More
Galectin Therapeutics Faces 28.9% Stock Drop Following FDA Response on Belapectin Trial
- Significant Stock Drop: Galectin Therapeutics experienced a stock price decline of $1.78, or 28.9%, closing at $4.38 per share following the FDA's feedback on its belapectin clinical trial design, indicating market concerns about the company's future prospects.
- Change in FDA Communication: The FDA converted the company's initial request for an in-person or teleconference meeting into a written response, and while there is alignment on the proposed patient population for a registration trial, unresolved key aspects of the trial design may hinder future clinical progress.
- Legal Investigation Initiated: Pomerantz LLP is investigating whether Galectin and its executives have engaged in securities fraud or other unlawful business practices, which could expose the company to legal risks and further impact shareholder confidence.
- Increased Investor Scrutiny: The sharp stock decline and the initiation of a legal investigation have significantly heightened investor attention on Galectin, potentially leading to more investors seeking to join class action lawsuits to protect their interests.
See More
Galectin Secures $10M Credit Line, FDA Provides Guidance on Regulatory Pathway
- Credit Support: Galectin Therapeutics Inc. secured a $10 million credit line, ensuring funding to cover expected expenditures through March 2027, thereby enhancing its R&D capabilities in the NASH cirrhosis treatment space.
- FDA Guidance: The FDA provided written feedback on Galectin's regulatory pathway for belapectin, marking a significant advancement in the company's drug development efforts, which could expedite its product's market entry.
- Market Reaction: Galectin's stock rose by 1% to $4.03 in Wednesday's trading, reflecting investor optimism regarding its financing and FDA support.
- Strategic Implications: This credit line and FDA guidance will provide Galectin with essential funding and regulatory backing in the competitive biopharmaceutical market, aiding its future clinical trials and market launch efforts.
See More
Galectin Therapeutics (GALT) Price Target Raised by 83.33% to $11.22
Price Target Update: The average one-year price target for Galectin Therapeutics (NasdaqCM:GALT) has been raised to $11.22 per share, reflecting an 83.33% increase from the previous estimate of $6.12, with a potential upside of 156.16% from the last closing price of $4.38.
Fund Sentiment: There are currently 122 funds reporting positions in Galectin Therapeutics, a decrease of 27 funds (18.12%) from the last quarter, while the average portfolio weight dedicated to GALT has increased by 41.86%.
Shareholder Activity: Notable shareholders include Vanguard Total Stock Market Index Fund and Advisor Group Holdings, with varying changes in their shareholdings, including increases in portfolio allocations for some funds.
Market Outlook: The put/call ratio for GALT stands at 0.09, indicating a bullish sentiment among investors, suggesting optimism about the stock's future performance.
See More
